- Home
- PHGE vs NUAI Comparison
PHGE vs NUAI Comparison
Compare PHGE & NUAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- NUAI
- Stock Information
- Founded
- PHGE 2015
- NUAI N/A
- Country
- PHGE Israel
- NUAI United States
- Employees
- PHGE N/A
- NUAI N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- NUAI Oil & Gas Production
- Sector
- PHGE Health Care
- NUAI Energy
- Exchange
- PHGE Nasdaq
- NUAI Nasdaq
- Market Cap
- PHGE 10.4M
- NUAI 11.3M
- IPO Year
- PHGE N/A
- NUAI N/A
- Fundamental
- Price
- PHGE $0.52
- NUAI $0.38
- Analyst Decision
- PHGE Strong Buy
- NUAI
- Analyst Count
- PHGE 1
- NUAI 0
- Target Price
- PHGE $15.00
- NUAI N/A
- AVG Volume (30 Days)
- PHGE 991.6K
- NUAI 1.4M
- Earning Date
- PHGE 08-13-2025
- NUAI 08-14-2025
- Dividend Yield
- PHGE N/A
- NUAI N/A
- EPS Growth
- PHGE N/A
- NUAI N/A
- EPS
- PHGE N/A
- NUAI N/A
- Revenue
- PHGE N/A
- NUAI $718,761.00
- Revenue This Year
- PHGE N/A
- NUAI N/A
- Revenue Next Year
- PHGE N/A
- NUAI N/A
- P/E Ratio
- PHGE N/A
- NUAI N/A
- Revenue Growth
- PHGE N/A
- NUAI 14.80
- 52 Week Low
- PHGE $0.34
- NUAI $0.37
- 52 Week High
- PHGE $1.23
- NUAI $12.29
- Technical
- Relative Strength Index (RSI)
- PHGE 50.56
- NUAI N/A
- Support Level
- PHGE $0.49
- NUAI N/A
- Resistance Level
- PHGE $0.56
- NUAI N/A
- Average True Range (ATR)
- PHGE 0.04
- NUAI 0.00
- MACD
- PHGE -0.01
- NUAI 0.00
- Stochastic Oscillator
- PHGE 49.28
- NUAI 0.00
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).